ALK and adenocarcinoma: The most prevalent alterations identified by RNA sequencing included fusions or exon skipping mutations involving therapy-associated genes MET (2.9%), ALK (1.7%), ROS1 (0.9%), and RET (0.7%), all of which were detected at a significantly higher frequency in adenocarcinoma cases (Figure 1C; Supplementary Table S1).